A preparation method of enzalutamide
The existing preparation of enzalumyl is solved by the method of condensation of compound 1 with tert-butanol, condensation of compound 2 with compound 3, cyclic integration of compound 4 with compound 5, and 6 with dichlorodiphenylmethane and methylamine. The problem of toxic reagents and impurity A production has achieved safe and suitable for industrial production of enzalubic acid.
Patent Information
- Application Number
- CN202410504858.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-04-25
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2044-04-25
AI Technical Summary
The use of highly toxic reagents in the existing preparation method of enzalubicide has resulted in high requirements for production equipment, high environmental pollution, and potential genotoxic impurities, which limits the applicability of industrial production.
Compound 1 and tert-butanol are used to condense compound 2, Compound 2 and Compound 3 are used to condense compound 4, Compound 4 and Compound 5 are used to cyclize compound 6, Compound 6 reacts with dichlorodiphenylmethane and reacts with low concentration methylamine. The production of enzalubic acid avoids the use of highly toxic agents and high concentrations of methylamine, and reduces the formation of impurity A.
The preparation of enzalubic acid without using highly toxic reagents is realized, which reduces the generation of impurity A, simplifies the post-treatment steps, is suitable for industrial production, and improves product safety.
Smart Images

Figure BDA0004809946590000011 
Figure BDA0004809946590000021 
Figure BDA0004809946590000022
Abstract
Description
Technical Field
[0001] The invention belongs to the field of drug synthesis, and specifically relates to a method for preparing enzalutamide. Background Art
[0002] Prostate cancer is one of the most common malignant tumors in men. In recent years, the incidence of prostate cancer in China has been on the rise, and most of the patients are already in the middle and late stages when they are discovered. Studies have shown that androgens play an important role in the occurrence and development of prostate cancer. At present, first-line endocrine therapy is the standard treatment for the initial treatment of advanced prostate cancer. Although this treatment method is effective for most patients in the initial stage, after a median treatment time of 14 to 30 months, almost all patients' lesions will gradually develop into castration-resistant prostate cancer (CRPC), with a median survival time of 1 to 2 years. Although docetaxel is approved for first-line chemotherapy of CRPC, the treatment method is single. At the same time, some patients cannot tolerate the toxicity of chemotherapy. Therefore, new effective and less toxic anti-tumor drugs are still needed for such patients.
[0003] Enzalutamide (4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thione-1-imidazolidinyl]-2-fluoro-N-methylbenzamide) was jointly developed by Medivation and Astellas. It was first approved for marketing by the US FDA on August 31, 2012, and then approved for marketing by the European EMA on June 21, 2013, and approved for marketing by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) on March 24, 2014. It is marketed by Astellas under the trade name Xtandi. Enzalutamide is an androgen receptor inhibitor that can reduce the proliferation of prostate cancer cells and induce their death. The drug is used to treat patients with metastatic castration-resistant prostate cancer who have previously received docetaxel therapy.
[0004] Enzalutamide has the structure shown below:
[0005]
[0006] The methods for synthesizing enzalutamide disclosed in the prior art mainly include:
[0007] Prior art WO2011106570 reports the following routes 1 and 2. The second step of route 1 requires the use of highly toxic methyl iodide, which places extremely high demands on production equipment and limits industrial applications. The last step of route 2 utilizes highly toxic and foul-smelling thiophosgene, which also has low reaction activity and a low overall yield.
[0008]
[0009] Route 1
[0010]
[0011] Route 2
[0012] The prior art CN104803918A improves the route reported in WO2011106570 and discloses a preparation method as shown in the following route 3. The preparation method avoids the use of highly toxic substances such as methyl iodide and thiophosgene. A methylamine solution is used in the last step to generate methylamine groups, but a high-concentration methylamine solution is used and the methylamine is greatly excessive. The problems of this route 3 are: (1) a large amount of acid needs to be added after the last step of the reaction is completed to neutralize the excess methylamine, which makes wastewater treatment very complicated and causes great environmental pollution; (2) during the reaction process of the last step, the benzene ring of the raw material has a methyl carboxylate group, which is a strong electron-pulling group, resulting in a relatively high activity of the ortho-fluorine atom, which is easily replaced by the methylamine solution to generate excessive methylamine impurities (see Figure 1 The inventors of the present application found that the content of peak 9# is usually around 0.1% to 0.2%, with the impurity code ENZ-A. This impurity has properties very similar to those of enzalutamide and is very difficult to purify, which limits industrial production. This impurity contains an aniline structure and is a potential genotoxic impurity that needs to be controlled.
[0013]
[0014] Therefore, there is an urgent need for a preparation method of enzalutamide that does not use highly toxic reagents, has a safe product and is suitable for industrial production. Summary of the invention
[0015] In view of the defects of the preparation method of enzalutamide in the prior art, the purpose of the present invention is to provide a new method for preparing enzalutamide, which does not use highly toxic reagents and has less potential genotoxic impurity by-products in the reaction solution in the last step.
[0016] The present invention provides a method for preparing enzalutamide, comprising the following steps:
[0017] (1) Compound 1 undergoes a condensation reaction with tert-butyl alcohol to generate compound 2. The reaction formula is as follows:
[0018]
[0019] In another preferred embodiment, the condensation reaction in step (1) is carried out in the presence of an activator.
[0020] In another preferred embodiment, the condensation reaction in step (1) is carried out in the presence of an activator and an acid binding agent.
[0021] In another preferred embodiment, the activator is selected from N,N'-dicyclohexylcarbodiimide (DCC), carbonyldiimidazole, thionyl chloride, oxalyl chloride, more preferably, DCC.
[0022] In another preferred embodiment, the acid binding agent is selected from triethylamine, diisopropylethylamine, pyridine, N-methylmorpholine, potassium carbonate, potassium phosphate and the like.
[0023] In another preferred embodiment, the weight-to-volume ratio of compound 1 to tert-butanol is 1-4 g / mL.
[0024] In another preferred embodiment, the molar ratio of compound 1 to the activator is 1:1-3, more preferably 1:1.0-1.5.
[0025] In another preferred embodiment, the solvent used in the reaction of step (1) is selected from dichloromethane, chloroform, toluene, or a combination thereof.
[0026] In another preferred embodiment, the temperature of the condensation reaction in step (1) is 0 to 40°C. In another preferred embodiment, step
[0027] The condensation reaction of (1) is carried out for 15 to 30 hours.
[0028] In another preferred embodiment, the preparation method of enzalutamide comprises the following steps:
[0029] (2) Compound 2 and compound 3 undergo condensation reaction to generate compound 4. The reaction formula is as follows:
[0030]
[0031] In another preferred embodiment, the condensation reaction of step (2) is carried out in the presence of a copper catalyst and an acid binding agent. In another preferred embodiment, the copper catalyst is selected from cuprous iodide, cuprous chloride, cuprous bromide, and more preferably cuprous iodide. In another preferred embodiment, the acid binding agent is selected from an inorganic base and / or an organic base. In another preferred embodiment, the inorganic base is selected from sodium carbonate, potassium carbonate, potassium phosphate, potassium tert-butoxide, sodium bicarbonate, or a combination thereof. In another preferred embodiment, the organic base is selected from triethylamine, diisopropylethylamine, pyridine, N-methylmorpholine, or a combination thereof.
[0032] In another preferred embodiment, the molar ratio of compound 2 to compound 3 is 1:1-3, more preferably 1:1.5-2.5.
[0033] In another preferred embodiment, the molar ratio of compound 2 to the copper salt catalyst and the acid binding agent is 1:0.001-0.1:1-3, more preferably 1:0.005-0.05:1.5-2.5.
[0034] In another preferred embodiment, the solvent used in the condensation reaction of step (2) is selected from dimethyl sulfoxide, N-methylpyrrolidone, isopropyl acetate, toluene, or a combination thereof.
[0035] In another preferred embodiment, the condensation reaction temperature of step (2) is 70-150°C, more preferably 80-110°C.
[0036] In another preferred embodiment, the preparation method of enzalutamide comprises the following steps:
[0037] (3) Compound 4 and compound 5 undergo cyclization reaction to generate compound 6. The reaction formula is as follows:
[0038]
[0039] In another preferred embodiment, the molar ratio of compound 4 to compound 5 is 1:1.0-3.0, more preferably, 1:1.2-1.5.
[0040] In another preferred embodiment, in step (3), the cyclization reaction temperature is 40 to 120°C, more preferably, 50 to 90°C.
[0041] In another preferred embodiment, in step (3), the cyclization reaction is carried out in an inert gas atmosphere, preferably, the inert gas is selected from nitrogen.
[0042] In another preferred embodiment, in step (3), the solvent used in the cyclization reaction is selected from dimethyl sulfoxide, N-methylpyrrolidone, isopropyl acetate or a combination thereof.
[0043] In another preferred embodiment, the preparation method of enzalutamide comprises the following steps:
[0044] (4) Compound 6 first reacts with dichlorodiphenylmethane, and the resulting intermediate then reacts with methylamine to generate enzalutamide. The reaction formula is as follows:
[0045]
[0046] In another preferred embodiment, step (4) comprises the following steps:
[0047] (4-a) Compound 6, in the presence of a Lewis acid, reacts with dichlorodiphenylmethane until compound 6 is completely converted,
[0048] (4-b) Adding an organic base and a methylamine salt to the reaction solution of step (4-a) to react and generate enzalutamide.
[0049] In another preferred embodiment, in step (4-a), the Lewis acid is selected from tin chloride, tin bromide, titanium chloride, titanium bromide, bismuth chloride, bismuth bromide, bismuth iodide, or a combination thereof, more preferably, bismuth chloride.
[0050] In another preferred embodiment, in step (4-a), the molar ratio of compound 6 to dichlorodiphenylmethane and Lewis acid is 1:1-3:0.001-0.2, more preferably, 1:1.1-1.5:0.05-0.1.
[0051] In another preferred embodiment, in step (4-b), the reaction temperature is 0 to 40°C, and the reaction time is 0.5 to 2 hours.
[0052] In another preferred embodiment, in step (4-b), the methylamine salt is selected from methylamine hydrochloride and / or methylamine sulfate.
[0053] In another preferred embodiment, the organic base is selected from triethylamine, diisopropylethylamine, pyridine, N-methylmorpholine or a combination thereof, more preferably triethylamine.
[0054] In another preferred embodiment, in step (4-b), the molar ratio of compound 6 to methylamine salt and organic base is 1:1-2.5:1-5, more preferably, 1:1.1-1.5:1.5-3.
[0055] In another preferred embodiment, in step (4-b), during the process of adding the base and methylamine, the system temperature is maintained at -5 to 10°C. After the addition is complete, the reaction is carried out at this temperature for 0.5 to 2 hours, and then at 5°C to 40°C for 1 to 3 hours.
[0056] In another preferred embodiment, in step (4), the solvent used in the reaction is selected from dichloromethane, chloroform, toluene or a combination thereof. BRIEF DESCRIPTION OF THE DRAWINGS
[0057] Figure 1 The inventor of this application obtained the HPLC spectrum of the reaction solution according to the preparation method disclosed in the prior art CN104803918A, wherein the 9# peak (RT=28.960min) is impurity A, wherein the content of impurity A is 0.19%;
[0058] Figure 2 This is the HPLC spectrum of the reaction solution obtained in Example 4-1 of the present invention, wherein the 8# peak (RT=30.222 min) is impurity A, and the content of impurity A is 0.0289%;
[0059] Figure 3 This is the HPLC spectrum of the final product Enzalutamide obtained in Example 4-1 of the present invention, wherein Peak 3# (RT=36.359 min) is impurity A, and the content of impurity A is 0.013%;
[0060] Figure 4This is the HPLC spectrum of the reaction solution obtained in Example 4-2 of the present invention, wherein the 5# peak (RT=36.374min) is impurity A, and the content of impurity A is 0.024%;
[0061] Figure 5 This is the HPLC spectrum of the final product enzalutamide obtained in Example 4-2 of the present invention, in which there is no peak of impurity A. DETAILED DESCRIPTION
[0062] In view of the defects of the preparation method of enzalutamide in the prior art, the inventors of the present application have developed a new preparation method of enzalutamide after in-depth research. This method does not require highly toxic reagents, and the last step uses low concentration of methylamine to react with the intermediate compound 6 containing tert-butoxyacyl group, which greatly reduces the generation of impurities with potential genotoxicity.
[0063] The inventors of the present application have studied the preparation method of enzalutamide and found that impurity A is produced when preparing enzalutamide according to the last step disclosed in the prior art CN104803918A. After multiple batches of verification, its content in the reaction solution is about 0.2%. After the synthesis and structural identification of the impurity, the structure of the impurity is confirmed as follows:
[0064]
[0065] The preparation process of impurity A is as follows: 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-benzoic acid methyl ester (i.e., compound F disclosed in CN104803918A) is added to a tetrahydrofuran solution of methylamine, and the mixture is reacted at 25 degrees for 24 hours to obtain impurity A. Impurity A is separated and purified and subjected to nuclear magnetic resonance and mass spectrometry detection.
[0066] The H NMR spectrum data of impurity A are shown in Table 1 below.
[0067] Table 1
[0068]
[0069] The mass spectrum data of impurity A is: [M+H] + 476 peak (Instrument model: Agilent 6400 LC-MS / MS, test conditions: ESI source)
[0070] The impurity A contains a secondary amine group and is a potential genotoxic impurity. The method disclosed in the prior art CN104803918A uses a large excess of high-concentration methylamine and 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-imidazole-1-yl)-2-fluoro-benzoic acid methyl ester (compound F) to form the above impurity A. The reason is that this is a typical nucleophilic substitution reaction. The fluorine atom on the benzene ring itself is not highly active and is generally difficult to be directly replaced by methylamine. However, there is a strong electron-pulling group, methyl carboxylate, on the benzene ring. The activity of the fluorine atom is greatly improved, and it is easy to be directly replaced by high-concentration methylamine to generate dimethylamine impurities.
[0071] When the inventors of the present application prepared enzalutamide according to the last step of the method disclosed in the prior art CN104803918A, they also tried to reduce the concentration and dosage of the methylamine solution, but the result was that the reaction was very slow and the raw materials did not react completely. If the temperature was increased, the reaction could be completed, but the impurity A became significantly larger. Even after recrystallization with isopropanol, a large amount of impurity A still existed in the product.
[0072] The inventors of the present application have found that in the process of preparing enzalutamide by first reacting compound 6 with dichlorodiphenylmethane, and then reacting the generated intermediate with methylamine to generate enzalutamide, when 1.1 to 1.5 equiv (equivalent) of methylamine is added, the substrate can be completely converted, and the content of impurity A is greatly reduced. After multiple batches of experiments, the content of impurity A in the reaction solution is less than 0.03%. After treating the reaction solution and recrystallizing the obtained final product with isopropanol, impurity A is basically undetectable, which meets the requirements of the preparation for the raw material drug. The reason why the preparation method of the present invention produces very little impurity A may be that the nucleophilic ability of low-concentration methylamine is relatively weak, and basically no excessive methylamine impurities are produced.
[0073] In a specific embodiment of the present invention, the preparation method of enzalutamide comprises the following steps:
[0074] (1) Compound 1 undergoes a condensation reaction with tert-butyl alcohol to generate compound 2.
[0075] (2) Compound 2 undergoes a condensation reaction with compound 3 to generate compound 4.
[0076] (3) Compound 4 undergoes a cyclization reaction with compound 5 to generate compound 6.
[0077] (4) Compound 6 first reacts with dichlorodiphenylmethane, and the resulting intermediate then reacts with methylamine to generate enzalutamide. The reaction formula is as follows:
[0078]
[0079] In step (1), the activating agent used includes but is not limited to N, N'-dicyclohexylcarbodiimide (DCC), carbonyl diimidazole, thionyl chloride, and oxalyl chloride. In a specific embodiment, the activating agent used in step (1) is DCC. After the reaction is completed, the reaction solution is washed with alkaline water and water in turn, and the solvent is removed. The residue is recrystallized from acetone to obtain the target product. In a specific embodiment, the activating agent used in step (1) is carbonyl diimidazole. After the reaction is completed, the reaction solution is washed with acidic water and water in turn, and the solvent is removed. The residue is recrystallized from acetone to obtain the target product.
[0080] In step (2), the copper catalyst used in the condensation reaction includes but is not limited to cuprous iodide and cuprous chloride; the acid binding agent used in the condensation reaction includes but is not limited to sodium carbonate, potassium carbonate, potassium phosphate, triethylamine, pyridine, etc. In a specific embodiment, after the reaction in step (2) is completed, the reaction solution is filtered to remove solid salts, and after the filtrate is concentrated, the residue is filtered using acetone solution to further remove solid salts, and the filtrate is concentrated again to 1 / 2 to 1 / 3 of the volume, water is added, and slurry is performed, and the target product is obtained by filtering.
[0081] In a specific embodiment, in step (3), compound 4 reacts with compound 5 at 50-90° C. to generate compound 6. After the reaction is completed, isopropanol is added to the reaction solution to quench excess compound 5. After compound 5 is completely quenched, the reaction solution is concentrated and the resulting residue is recrystallized twice using isopropanol to obtain the target product.
[0082] In step (4), compound 6 first reacts with dichlorodiphenylmethane, and the intermediate (acyl chloride compound) generated is then reacted with methylamine to generate enzalutamide. The reaction of compound 6 with dichlorodiphenylmethane is carried out in the presence of a Lewis acid, and the Lewis acid includes but is not limited to tin chloride, tin bromide, titanium chloride, titanium bromide, bismuth chloride, bismuth bromide, bismuth iodide, etc. In a specific embodiment, the intermediate generated by the reaction of compound 6 with dichlorodiphenylmethane is then reacted with a methylamine salt in the presence of an organic base to generate enzalutamide, and the base includes but is not limited to triethylamine, diisopropylethylamine, pyridine, and N-methylmorpholine. In a specific embodiment, after the reaction of step (2) is completed, the reaction solution is washed with an acidic aqueous solution, an alkaline aqueous solution, and water in sequence, and then concentrated. The residue obtained is recrystallized using isopropanol to obtain the target product.
[0083] During the reaction of the present invention, if the disappearance of the raw material is detected by commonly used means in the art (eg, thin layer chromatography or liquid chromatography), it can be determined that the key raw material has been completely converted and the reaction is complete.
[0084] Compared with the prior art, the preparation method of enzalutamide of the present invention has the following beneficial effects:
[0085] (1) No highly toxic reagents are used, the content of impurity A by-product in the reaction solution is low, and the final product enzalutamide obtained by a single recrystallization does not contain the by-product, or the content does not exceed 0.015%;
[0086] (2) The post-processing of each step is relatively simple, and the target product can be obtained by only recrystallization or slurrying and stirring, which is suitable for industrial production.
[0087] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples that do not specify specific conditions are usually carried out under normal conditions or according to the conditions recommended by the manufacturer. Unless otherwise specified, percentages and parts are weight percentages and weight parts. The reagents or raw materials used in the following examples are generally commercially available, or can be prepared according to the methods disclosed in the prior art, unless otherwise stated.
[0088] The instrument used for purity detection in the following examples is Agilent 6400 LC-MS / MS.
[0089] Example 1-1 Preparation of Compound 2
[0090] In a 10L three-necked flask equipped with a mechanical stirrer and a reflux condenser, add 438g (2.0mol, 1.0equiv) of raw material 2-fluoro-4-bromobenzoic acid, 200ml of tert-butyl alcohol, and 3000ml of dichloromethane. After stirring and dissolving, cool to 0°C, slowly drop a mixture of DCC (453g (2.2mol, 1.1equiv) and dichloromethane (2000ml). After the addition is completed, heat to room temperature and react for 24 hours. After the reaction is completed, wash once with 1mol / L sodium hydroxide solution and 3000ml of drinking water, respectively, concentrate under reduced pressure to remove dichloromethane, add 1500ml of acetone, heat to dissolve, concentrate to about 1000ml under normal pressure, cool to room temperature and stir for 2 hours, filter, and dry the obtained filter cake to obtain 499.7g 2-Fluoro-4-bromobenzoic acid tert-butyl ester (Compound 2), HPLC purity 99.1%, molar yield 90.0%. MS: m / z = 275 [M+H] + .
[0091] Example 1-2 Preparation of Compound 2
[0092] In a 10L three-necked flask equipped with a mechanical stirrer and a reflux condenser, 438g (2.0mol, 1.0equiv) of raw material 2-fluoro-4-bromobenzoic acid, 200ml of tert-butanol, and 3000ml of dichloromethane were added, stirred until dissolved, and then the temperature was lowered to 0°C, 356g (2.2mol, 1.1equiv) of carbonyldiimidazole was slowly added, stirred for reaction for 2 hours, 200ml of tert-butanol was added dropwise, and the reaction was continued for 24 hours. After the reaction was completed, it was washed once with a 1mol / L hydrochloric acid solution and 3000ml of drinking water, respectively, and concentrated under reduced pressure to remove dichloromethane, 1500ml of acetone was added, heated to dissolve, concentrated to about 1000ml under normal pressure, cooled to room temperature and stirred for 2 hours, filtered, and the resulting filter cake was dried to obtain 480.7g of tert-butyl 2-fluoro-4-bromobenzoate (Compound 2), HPLC purity 99.0%, and molar yield 86.5%. MS: m / z = 275 [M+H] + .
[0093] Example 2-1 Preparation of Compound 4
[0094] In a 5.0L three-necked flask equipped with mechanical stirring and a reflux condenser, dry nitrogen was purged for half an hour, and the raw materials 2-fluoro-4-bromobenzoic acid tert-butyl ester 277.6g (1.0mol, 1.0equiv, purity 99.1%), 2-methylalanine methyl ester hydrochloride 307g (2.0mol, 2.0equiv), cuprous iodide 1.9g (0.01mol, 0.01equiv), potassium carbonate 276g (2.0mol, 2.0equiv), DMSO ( 3000ml of dimethyl sulfoxide) was added, heated to 80°C for 5 hours, cooled and filtered to remove solid salts, and the filtrate was concentrated to dryness under high vacuum. The residue was added to 1500ml of acetone and refluxed for 2 hours, filtered while hot, and the filtrate was concentrated to about 600ml under normal pressure, cooled to room temperature and stirred for 2 hours, filtered, and the filter cake was slurried with 1000ml of drinking water at room temperature for 2 hours, filtered, and the filter cake was dried to obtain 275.5g of compound 4, HPLC purity 98.5%, molar yield 87.2%. MS: m / z=312[M+H] + .
[0095] Example 2-2 Preparation of Compound 4
[0096] In a 5.0L three-necked flask equipped with mechanical stirring and a reflux condenser, dry nitrogen was purged for half an hour, and the raw materials 2-fluoro-4-bromobenzoic acid tert-butyl ester 277.6g (1.0mol, 1.0equiv), 2-methylalanine methyl ester hydrochloride 307g (2.0mol, 2.0equiv), cuprous chloride 19.8g (0.2mol, 0.2equiv), triethylamine 303g (3.0mol, 3.0equiv), NMP (N-methylpyrrolidone) were quickly added. )3000ml, heated to 100℃ and reacted for 5 hours. After the reaction was completed, the solid salt was removed by cooling and filtration. The filtrate was concentrated to dryness under high vacuum and reduced pressure. The obtained residue was added to 1500ml of acetone and refluxed for 2 hours. It was filtered while hot. The filtrate was concentrated to about 600ml under normal pressure, cooled to room temperature and stirred for 2 hours, filtered, and the obtained filter cake was slurried with 1000ml of drinking water at room temperature for 2 hours, filtered, and the obtained filter cake was dried to obtain 256.2g of compound 4, HPLC purity 98.2%, molar yield 80.8%. MS: m / z=312[M+H] + .
[0097] Example 3-1 Preparation of Compound 6
[0098] 372.99g of compound 4 (1.18mol, 1.0equiv, purity 98.5%) was added to 1500ml of DMSO, and a mixed solution of 403.5g (1.77mol, 1.5equiv) of 4-isothiocyanato-2-(trifluoromethyl)benzonitrile (compound 5) and DMSO solution (1000ml) was added dropwise at room temperature, nitrogen was continuously introduced, the temperature was slowly raised to 50°C, 100ml of isopropanol was added after reaction for 5 hours, the reaction was continued for 2 hours, and the mixture was concentrated to dryness under reduced pressure. 500ml of isopropanol was added to the residue, the temperature was raised to reflux for 1 hour, the temperature was lowered to room temperature, a solid was precipitated, and the filter cake was crystallized again with 500ml of isopropanol, and rinsed with 200ml of ice isopropanol, and dried to obtain 448.5g of compound 6, with an HPLC purity of 99.5% and a molar yield of 74.6%. MS: m / z=508[M+H]+.
[0099] Example 3-2 Preparation of Compound 6
[0100] 372.99g of compound 4 (1.18mol, 1.0equiv, purity 98.5%) was added to 1500ml of NMP, and a mixed solution of 403.5g (1.77mol, 1.5equiv) of 4-isothiocyanato-2-(trifluoromethyl)benzonitrile (compound 5) and NMP solution (1000ml) was added dropwise at room temperature, nitrogen was continuously introduced, the temperature was slowly raised to 90°C, 100ml of isopropanol was added after reaction for 5 hours, the reaction was continued for 2 hours, and the mixture was concentrated to dryness under reduced pressure. The residue was added to 500ml of isopropanol, the temperature was raised to reflux for 1 hour, the temperature was lowered to room temperature, a solid was precipitated, and the solid was filtered. The filter cake was crystallized again with 500ml of isopropanol, and the filter cake was rinsed with 200ml of ice isopropanol and dried to obtain 429.5g of compound 6 with a HPLC purity of 99.3% and a molar yield of 71.2%. MS: m / z=508[M+H]+.
[0101] Example 4-1 Preparation of Enzalutamide
[0102] To a 5L reaction bottle, 306.0g of compound 6 (0.6mol, 1.0equiv, purity 99.5%), 171g of dichlorodiphenylmethane (0.72mol, 1.2equiv), and 1.5L of dichloroethane (DCE) were added as solvents, 1.9g of bismuth chloride (0.006mol, 0.01equiv) was slowly added, and the mixture was stirred at room temperature for 1 hour, cooled to 0-5°C, 202.4g of triethylamine (2.0mol, 3.2equiv) was added, and 44.5g of methylamine hydrochloride (0.66mol, 1.1equiv) was slowly added. After reacting for 1 hour, the mixture was heated to room temperature and continued to react for two hours. 1.0L of 2.0N dilute hydrochloric acid and 1.0L of 2.0N sodium hydroxide solution were added and stirred for 20 minutes, and the layers were separated. The dichloroethane layer was then treated with 1.0L of 5% The mixture was washed once with disodium EDTA solution and 1.0 L of drinking water, concentrated to dryness, a small amount of isopropanol (200 ml) was added to the residue, and concentrated to dryness again to fully remove dichloromethane. The residue was added to 500 mL of isopropanol, refluxed to dissolve, cooled to precipitate solids, filtered and dried to obtain 253.9 g of enzalutamide with a purity of 99.87% and a molar yield of 91.0%, wherein the content of impurity A was 0.013%.
[0103] The product was confirmed to be enzalutamide by HPLC and NMR. ESI-MS (m / z): 465 [M+H]+;
[0104] 1H NMR(500MHz,DMSO-d6)δ1.53(s,6H),2.79(d,3H),7.41-7.31(m,1H),7.43-7.42(d,1H) ),7.76(s,1H),8.06(s,1H),8.28-8.27(d,1H),8.39-8.38(d,1H),8.42-8.41(d,1H).
[0105] 13C NMR(500MHz,DMSO-d6)δ183.17,177.82,166.51,162.85,141.41,141.02,139.36,137.04,134.5 6,133.97,131.13,129.21,128.30,126.22,121.20,118.09,111.84,69.69,29.37,26.06,26.05.
[0106] Example 4-2 Preparation of Enzalutamide
[0107] To a 500mL reaction bottle, 30.6g of compound 6 (0.06mol, 1.0equiv, purity 99.3%), 28.4g of dichlorodiphenylmethane (0.12mol, 2.0equiv), and 150mL of chloroform as solvent were added, 1.2g of tin dichloride (0.006mol, 0.10equiv) was slowly added, and the mixture was stirred at room temperature for 1 hour, and the temperature was lowered to 0-5°C, 25.8g of triethylamine (0.2mol, 3.3equiv) was added, and 9.6g of methylamine sulfate (0.06mol, 1.0equiv) was slowly added. After the reaction for 1 hour, the mixture was heated to room temperature and the reaction was continued for two hours. 100mL of 2.0N dilute hydrochloric acid and 100mL of 2.0N sodium hydroxide solution were added and stirred for 20 minutes. The layers were separated, and the chloroform layer was separated by 100mL of ... The mixture was washed once with 5% disodium EDTA solution and 100 mL of drinking water, concentrated to dryness, a small amount of isopropanol (20 mL) was added to the residue, and concentrated to dryness again to fully remove dichloromethane. The residue was added to 50 mL of isopropanol, refluxed to dissolve, cooled, solids precipitated, filtered and dried to obtain 24.4 g of enzalutamide with a purity of 99.88% and a molar yield of 87.5%, wherein the content of impurity A was 0.
[0108] The product was confirmed to be enzalutamide by HPLC and NMR.
[0109] Example 4-3 Preparation of Enzalutamide
[0110] To a 500mL reaction bottle, 30.6g of compound 6 (0.06mol, 1.0equiv, purity 99.3%), 21.3g of dichlorodiphenylmethane (0.09mol, 1.5equiv), and 150mL of dichloromethane were added as solvent, 2.7g of bismuth bromide (0.006mol, 0.01equiv) was slowly added, and the mixture was stirred at room temperature for 1 hour, and the temperature was lowered to 0-5°C, 30.3g of N-methylmorpholine (0.3mol, 5.0equiv) was added, and 10.1g of methylamine hydrochloride (0.15mol, 2.5equiv) was slowly added. After the reaction for 1 hour, the mixture was heated to room temperature and the reaction was continued for two hours. 100mL of 2.0N dilute hydrochloric acid and 100mL of 2.0N sodium hydroxide solution were added and stirred for 20 minutes. The layers were separated, and the dichloromethane layer was separated by 100mL of 100mL of 100mL of 2 ... The mixture was washed once with 5% disodium EDTA solution and 100 mL of drinking water, concentrated to dryness, a small amount of isopropanol (20 mL) was added to the residue, and concentrated to dryness again to fully remove dichloromethane. The residue was added to 50 mL of isopropanol, refluxed to dissolve, cooled, solids precipitated, filtered and dried to obtain 24.2 g of enzalutamide with a purity of 99.5% and a molar yield of 86.4%, wherein the content of impurity A was 0.01%.
[0111] The product was confirmed to be enzalutamide by HPLC and NMR.
[0112] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.
Claims
1. A method for preparing enzalutamide, characterized in that: The preparation method comprises the following steps: (1) Compound 1 undergoes a condensation reaction with tert-butyl alcohol to generate compound 2. The reaction formula is as follows: (2) Compound 2 and compound 3 undergo condensation reaction to generate compound 4. The reaction formula is as follows: (3) Compound 4 and compound 5 undergo cyclization reaction to generate compound 6. The reaction formula is as follows: (4) Compound 6 first reacts with dichlorodiphenylmethane, and the resulting intermediate then reacts with methylamine to generate enzalutamide. The reaction formula is as follows:
2. The method for preparing enzalutamide according to claim 1, characterized in that: The condensation reaction of step (1) is carried out in the presence of an activator and, optionally, an acid-binding agent.
3. The method for preparing enzalutamide according to claim 1, characterized in that: The activator is selected from DCC (N,N'-dicyclohexylcarbodiimide), carbonyldiimidazole, thionyl chloride, oxalyl chloride, or a combination thereof.
4. The method for preparing enzalutamide according to claim 1, characterized in that: The acid binding agent is selected from triethylamine, diisopropylethylamine, pyridine, N-methylmorpholine, potassium carbonate, potassium phosphate, or a combination thereof.
5. The method for preparing enzalutamide according to claim 1, characterized in that: The condensation reaction in step (2) is carried out in the presence of a copper salt catalyst and an acid binding agent. The copper salt catalyst is selected from cuprous iodide, cuprous bromide, cuprous chloride or a combination thereof, The acid binding agent is selected from an inorganic base and / or an organic base, the inorganic base is selected from sodium carbonate, potassium carbonate, potassium phosphate, potassium tert-butoxide, sodium bicarbonate, or a combination thereof, and the organic base is selected from triethylamine, diisopropylethylamine, pyridine, N-methylmorpholine, or a combination thereof.
6. The method for preparing enzalutamide according to claim 5, characterized in that: The copper salt catalyst is selected from cuprous iodide.
7. The method for preparing enzalutamide according to claim 1, characterized in that: Step (4) comprises the following steps: (4-a) Compound 6, in the presence of a Lewis acid, reacts with dichlorodiphenylmethane until compound 6 is completely converted, (4-b) Adding an organic base and a methylamine salt to the reaction solution of step (4-a) to react and generate enzalutamide.
8. The method for preparing enzalutamide according to claim 7, characterized in that: The Lewis acid is selected from tin chloride, tin bromide, titanium chloride, titanium bromide, bismuth chloride, bismuth bromide, and bismuth iodide.
9. The method for preparing enzalutamide according to claim 7, characterized in that: The methylamine salt is selected from methylamine hydrochloride and / or methylamine sulfate.
10. The method for preparing enzalutamide according to claim 7, characterized in that: The organic base is selected from triethylamine, diisopropylethylamine, pyridine and N-methylmorpholine.
11. A method for preparing enzalutamide, characterized in that: The preparation method comprises the following steps: Compound 6 first reacts with dichlorodiphenylmethane, and the resulting intermediate then reacts with methylamine to generate enzalutamide. The reaction formula is as follows:
12. A method for preparing enzalutamide, characterized in that: The preparation method comprises the following steps: Compound 4 and compound 5 undergo cyclization reaction to generate compound 6. The reaction formula is as follows: Compound 6 first reacts with dichlorodiphenylmethane, and the resulting intermediate then reacts with methylamine to generate enzalutamide. The reaction formula is as follows:
13. A method for preparing enzalutamide, characterized in that: The preparation method comprises the following steps: Compound 2 and compound 3 undergo condensation reaction to generate compound 4. The reaction formula is as follows: Compound 4 and compound 5 undergo cyclization reaction to generate compound 6. The reaction formula is as follows: Compound 6 first reacts with dichlorodiphenylmethane, and the resulting intermediate then reacts with methylamine to generate enzalutamide. The reaction formula is as follows:
